Formycon AG (LON:0W4N)

Market Cap	384.82M
Revenue (ttm)	41.96M
Net Income (ttm)	-144.17M
Shares Out	n/a
EPS (ttm)	-8.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,721
Average Volume	4,818
Open	25.15
Previous Close	25.50
Day's Range	24.80 - 25.20
52-Week Range	19.10 - 64.30
Beta	0.80
RSI	60.99
Earnings Date	Nov 13, 2025

About Formycon AG

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company’s pipeline includes ustekinumab used in the treatment of Crohn’s disease, ulcerative colitis...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1999
• Employees: 250
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0W4N

Financial Performance

Financial numbers in EUR